Try Alerts Free   |   Login
Health Care › LABORATORY ANALYTICAL INSTRUMENTS

SEER Price Correlated With Financials For Seer

Free historical financial statements for Seer Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 5 quarters since 2021. Compare with SEER stock chart to see long term trends.

SEER Stock Compared to Quarterly

SEER Income Statement

Revenue, Net:3312000
Revenue Per Share:0.0534
Cost of Goods & Services Sold:2068000
Gross Profit:1244000
Selling, General & Admin Expense:14298000
Research & Development Expense:10732000
Total Operating Expenses:25030000
Operating Income:-23786000
Net Income:-23646000
Earnings Per Share, Basic:-0.38
Shares Outstanding, Basic Avg:62003504

SEER Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:875000
Net Cash from Operations:-19151000
Net Cash from Operations Per Share:-0.3089
Repurchases/Buybacks Common Stock:21000
Net Cash from Financing Activities:752000
Property, Plant & Equipment Purchases:1080000
Net Cash from Investing Activities:10920000
Net Change in Cash & Equivalents:-7479000

SEER Balance Sheet

Cash and Cash Equivalents:471800000
Accounts Receivable, Net:2793000
Inventories:3550000
Total Current Assets:457456000
Property, Plant & Equipment, Net:13654000
Total Assets:527085000
Total Short-Term Liabilities:11152000
Total Liabilities:40627000
COMPANY PROFILE
ORGANIZATION AND DESCRIPTION OF THE BUSINESS Seer, Inc. (the Company) was incorporated in Delaware on March 16, 2017, and is headquartered in Redwood City, California. In December 2020, the Company formed the wholly-owned subsidiary, Seer Securities Corporation, located in Massachusetts. The Company is a life sciences company focused on capturing deep molecular insights from the proteome to enable novel insights and breakthroughs in the understanding of biology and disease. Since inception, the Company has devoted its efforts principally to research, development and commercialization of its technology and products, recruiting management and technical staff, acquiring operating assets, and raising capital.

The Company is subject to a number of risks, similar to other early-stage life science companies, including, but not limited to, development and commercialization of its products, market acceptance of its products, development by its competitors of new technological innovations, protection of its intellectual property, and raising additional capital.

Public Offering

On February 1, 2021, the Company completed an underwritten public offering of 1,650,000 shares of its Class A common stock at a public offering price of $67.00 per share. The Company received net proceeds of $103.0 million after deducting offering costs, underwriting discounts, and commissions of $7.6 million.

Liquidity

As of March 31, 2022, the Company has incurred significant losses and has had negative cash flows from operations. As of March 31, 2022, the Company had cash, cash equivalents and investments of $471.8 million and an accumulated deficit of $150.2 million. Management expects to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while the Company makes investments to support its anticipated growth. The Company believes that its cash and cash equivalents balance as of March 31, 2022 provides sufficient capital resources to continue its operations for at least 12 months from the issuance date of the accompanying unaudited condensed consolidated financial statements.

Data imported from Seer Inc. SEC filings. Check original filings before making any investment decision.